RCKT - Rocket Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cranbury,
United States
Type: Equity
RCKT price evolution
RCKT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $40.45 | $37.17 | $57.81 | |
| Short term investments | $240.22 | $295.04 | $317.27 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $241.75 | $292.73 | $345.16 | $378.22 |
| Long term investments | $34.32 | |||
| Property, plant & equipment | $85.77 | $87.54 | $88.08 | $87.59 |
| Goodwill & intangible assets | $64.3 | $64.3 | $64.3 | |
| Total noncurrent assets | $153.69 | $154.28 | $188.12 | |
| Total investments | $240.22 | $295.04 | $351.59 | |
| Total assets | $393.69 | $446.41 | $499.44 | $566.34 |
| Current liabilities | ||||
| Accounts payable | $34.73 | $30.09 | $45.79 | |
| Deferred revenue | ||||
| Short long term debt | $2.86 | $2.87 | $2.72 | |
| Total current liabilities | $39.98 | $37.59 | $32.96 | $48.51 |
| Long term debt | $19.38 | $22.94 | $23.08 | $22.33 |
| Total noncurrent liabilities | $24.18 | $24.98 | $25.26 | |
| Total debt | $25.8 | $25.95 | $25.04 | |
| Total liabilities | $63.92 | $61.78 | $57.94 | $73.77 |
| Shareholders' equity | ||||
| Retained earnings | -$1157.79 | -$1091.07 | -$1021.42 | -$959.37 |
| Other shareholder equity | $0.21 | -$0.22 | -$0.14 | $0.32 |
| Total shareholder equity | $384.63 | $441.5 | $492.57 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $57.81 | $142.47 | $234.49 | $299.12 |
| Short term investments | $317.27 | $215.88 | $156.05 | $185.62 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $378.22 | $364.06 | $392.06 | $487.35 |
| Long term investments | $34.32 | $43.28 | ||
| Property, plant & equipment | $87.59 | $77.64 | $72.35 | $70.64 |
| Goodwill & intangible assets | $64.3 | $64.88 | $30.82 | $30.82 |
| Total noncurrent assets | $188.12 | $187.75 | $104.96 | $103.48 |
| Total investments | $351.59 | $259.15 | $156.05 | $185.62 |
| Total assets | $566.34 | $551.81 | $497.02 | $590.82 |
| Current liabilities | ||||
| Accounts payable | $45.79 | $36.66 | $19.61 | $25.47 |
| Deferred revenue | ||||
| Short long term debt | $2.72 | $2.51 | $2.55 | $7.14 |
| Total current liabilities | $48.51 | $39.17 | $22.17 | $32.62 |
| Long term debt | $22.33 | $19.27 | $20.05 | $54.55 |
| Total noncurrent liabilities | $25.26 | $22.95 | $20.13 | $54.69 |
| Total debt | $25.04 | $22.87 | $22.6 | $61.7 |
| Total liabilities | $73.77 | $62.12 | $42.3 | $87.31 |
| Shareholders' equity | ||||
| Retained earnings | -$959.37 | -$713.77 | -$491.91 | -$322.84 |
| Other shareholder equity | $0.32 | -$0.36 | -$0.16 | -$0.04 |
| Total shareholder equity | $492.57 | $489.69 | $454.72 | $503.52 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $46.34 | $45.23 | $41.74 | |
| Selling, general & administrative | $27.37 | $22.15 | $21.54 | |
| Total operating expenses | $69.42 | $73.71 | $67.38 | $63.28 |
| Operating income | -$73.71 | -$67.38 | -$63.28 | |
| Income from continuing operations | ||||
| EBIT | -$69.17 | -$61.58 | -$59.19 | |
| Income tax expense | ||||
| Interest expense | $0.86 | $0.47 | $0.47 | $0.47 |
| Net income | ||||
| Net income | -$66.72 | -$69.65 | -$62.05 | -$59.66 |
| Income (for common shares) | -$69.65 | -$62.05 | -$59.66 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $186.34 | $165.57 | $125.48 | $106.38 |
| Selling, general & administrative | $73.32 | $58.77 | $41.77 | $27.92 |
| Total operating expenses | $259.66 | $224.34 | $167.25 | $134.3 |
| Operating income | -$259.66 | -$224.34 | -$167.25 | -$134.3 |
| Income from continuing operations | ||||
| EBIT | -$243.72 | -$220 | -$166.09 | -$132.73 |
| Income tax expense | ||||
| Interest expense | $1.88 | $1.86 | $2.98 | $6.97 |
| Net income | ||||
| Net income | -$245.59 | -$221.86 | -$169.07 | -$139.7 |
| Income (for common shares) | -$245.59 | -$221.86 | -$169.07 | -$139.7 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$69.65 | -$62.05 | -$59.66 | |
| Operating activities | ||||
| Depreciation | $2.37 | $2.25 | $1.94 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.33 | $10.25 | $9.93 | |
| Total cash flows from operations | -$53.82 | -$56.86 | -$29.34 | |
| Investing activities | ||||
| Capital expenditures | -$1.93 | -$2.04 | -$4.65 | |
| Investments | $57.55 | $37.07 | -$136.16 | |
| Total cash flows from investing | $169.58 | $55.62 | $35.03 | -$140.81 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.53 | $1.18 | $0.39 | |
| Net borrowings | ||||
| Total cash flows from financing | $2.89 | $1.53 | $1.18 | $0.39 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $9.68 | $3.33 | -$20.64 | -$169.75 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$245.59 | -$221.86 | -$169.07 | -$139.7 |
| Operating activities | ||||
| Depreciation | $7.1 | $6.27 | $5.37 | $1.15 |
| Business acquisitions & disposals | $42.73 | |||
| Stock-based compensation | $39.41 | $31.01 | $29.24 | $18.57 |
| Total cash flows from operations | -$194.92 | -$178.14 | -$121.16 | -$74.64 |
| Investing activities | ||||
| Capital expenditures | -$16.47 | -$8.62 | -$7.71 | -$29.06 |
| Investments | -$81.59 | -$103.43 | $26.57 | -$67.53 |
| Total cash flows from investing | -$98.07 | -$69.33 | $18.85 | -$96.59 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $208.4 | $155.29 | $37.68 | $283.84 |
| Net borrowings | -$0.24 | |||
| Total cash flows from financing | $208.4 | $155.29 | $37.68 | $282.99 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$84.58 | -$92.18 | -$64.63 | $111.76 |
News
Fundamentals
| Market cap | $308.89M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 91.12M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$258.08M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -1.20 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.83 |
|---|---|
| ROA | -54.16% |
| ROE | N/A |
| Debt/Equity | 0.15 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.05 |
| Quick ratio | N/A |